The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
Deep Track Capital and affiliated entities filed an amended Schedule 13G reporting passive ownership of 2,161,510 shares of Oruka Therapeutics common stock, representing 4.47% of the class as of December 31, 2025. This percentage is based on 48,409,232 shares outstanding as of October 31, 2025, as reported in Oruka’s 10-Q. The filing states the shares are not held to change or influence control of Oruka Therapeutics.
The Vanguard Group reports beneficial ownership of 2,453,530 shares of Oruka Therapeutics Inc common stock, representing 5.06% of the class as of 12/31/2025. Vanguard has shared voting power over 291,185 shares and shared dispositive power over all 2,453,530 shares, with no sole voting or dispositive power.
The holdings are described as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Oruka Therapeutics. Vanguard states that its clients have the right to receive dividends and sale proceeds, with no single client holding more than 5%. Vanguard also notes an internal realignment effective 01/12/2026, after which certain subsidiaries or business divisions are expected to report beneficial ownership separately.
Oruka Therapeutics Chief Medical Officer Joana Goncalves received new equity awards in the form of stock and options. On January 23, 2026, she was granted 32,500 shares of common stock at a price of $0 per share, bringing her directly held common stock to 34,018 shares. This stock grant vests in equal sixteenth portions on each March 14, June 14, September 14, and December 14.
On the same date she was also granted an employee stock option for 130,000 shares of Oruka Therapeutics common stock at an exercise price of $34.39 per share. The option vests in 1/48 monthly installments starting from January 1, 2026 and is scheduled to expire on January 22, 2036. Both the stock and option positions are reported as held directly.
Oruka Therapeutics, Inc. disclosed that Chief Operating Officer Laura Sandler received new equity awards on January 23, 2026. She was granted 32,500 shares of common stock at a price of $0 per share, increasing her directly held common stock to 237,584 shares. The stock grant vests in 1/16 increments on each March 14, June 14, September 14 and December 14.
She also received an employee stock option covering 130,000 shares of common stock at an exercise price of $34.39 per share, expiring on January 22, 2036. This option vests as to 1/48 of the underlying shares monthly starting from January 1, 2026, and is held directly.
Oruka Therapeutics senior vice president of finance Arjun Agarwal reported new equity awards. On January 23, 2026, he received an employee stock option for 70,000 shares of common stock at an exercise price of $34.39 per share, with the option vesting in 1/48 monthly installments from January 1, 2026. He also acquired 17,500 shares of common stock at a stated price of $0, vesting in 1/16 installments on each March 14, June 14, September 14 and December 14. Following these transactions, he directly beneficially owned 19,258 common shares, including 1,758 shares previously acquired under the Oruka stock purchase plan.
Oruka Therapeutics, Inc. reported that Chief Executive Officer and director Lawrence Otto Klein received new equity awards on January 23, 2026. He was granted 306,700 employee stock options with an exercise price of $34.39 per share, covering the right to buy 306,700 shares of common stock, for which he paid $0 at grant. These options vest as to 1/48 of the underlying shares monthly starting January 1, 2026 and expire on January 22, 2036. In addition, he acquired 76,700 shares of common stock at a price of $0, bringing his directly held common stock position to 929,038 shares. That stock grant vests in 1/16 increments on each March 14, June 14, September 14, and December 14, or the prior trading day if needed.
Oruka Therapeutics, Inc. reported that its General Counsel, Paul T. Quinlan, received new equity awards on January 23, 2026.
He acquired 32,500 shares of common stock at a price of $0, held directly. This grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day).
Quinlan was also granted an employee stock option for 130,000 shares of common stock at an exercise price of $34.39 per share, expiring on January 22, 2036. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
Oruka Therapeutics director Carl Dambkowski reported receiving 116,483 shares of common stock on January 23, 2026. The Form 4 shows the shares were acquired at a price of $0.00 through a transaction coded "J," which the footnote explains as a pro-rata distribution from a limited liability company in which he is a member. After this distribution, he beneficially owns 116,483 shares of Oruka common stock in direct form.
BlackRock, Inc. has reported a passive ownership stake in Oruka Therapeutics, Inc. common stock. BlackRock beneficially owns 3,175,483 shares, representing 6.6% of Oruka’s outstanding common stock as of the event date of 12/31/2025. It has sole power to vote 3,128,050 shares and sole power to dispose of 3,175,483 shares, with no shared voting or dispositive power.
The filing states that the securities were acquired and are held in the ordinary course of business and are not intended to change or influence control of Oruka Therapeutics. Various underlying clients or investors have rights to dividends or sale proceeds, but no single person has more than five percent of the total outstanding common shares.
Oruka Therapeutics, Inc. Chief Medical Officer Joana Goncalves reported option and warrant exercises followed by stock sales. On January 15, 2026, she exercised an employee stock option for 3,500 shares of common stock at $6.84 per share and an employee warrant for another 3,500 shares at $7.8 per share.
That same day, she sold 4,381 shares of common stock at a weighted average price of $31.5626 and 2,619 shares at a weighted average price of $32.237, all under a Rule 10b5-1 trading plan entered into on September 19, 2025. After these transactions, she directly owned 1,518 shares of common stock, as well as 221,563 employee stock options and 192,992 employee warrants.